drugset / Trial / NCT06873789
A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors.
Timeline
- Start
- 2025-06-30
- Primary completion
- 2026-07-29
- Completion
- 2026-07-29
Outcome
Outcome not reported
Stopped (Business): “This was a strategic business decision. There were no safety concerns contributing to this decision.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INCB177054 | Unknown | — | — |
| Subject | Retifanlimab | Monoclonal antibody | — | — |